Cargando…
Discovering Synergistic Compounds with BYL-719 in PI3K Overactivated Basal-like PDXs
SIMPLE SUMMARY: Basal-like breast cancers comprise the majority of triple-negative breast cancers (TNBC) and lack effective treatment options that have a sustained response. Part of the reason that they are hard to eliminate is that they exhibit high levels of genomic instability and cellular divers...
Autores principales: | Boyd, David C., Zboril, Emily K., Olex, Amy L., Leftwich, Tess J., Hairr, Nicole S., Byers, Holly A., Valentine, Aaron D., Altman, Julia E., Alzubi, Mohammad A., Grible, Jacqueline M., Turner, Scott A., Ferreira-Gonzalez, Andrea, Dozmorov, Mikhail G., Harrell, J. Chuck |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001201/ https://www.ncbi.nlm.nih.gov/pubmed/36900375 http://dx.doi.org/10.3390/cancers15051582 |
Ejemplares similares
-
Transcriptomic changes underlying EGFR inhibitor resistance in human and mouse models of basal-like breast cancer
por: Rashid, Narmeen S., et al.
Publicado: (2022) -
Identification of nuclear export inhibitor-based combination therapies in preclinical models of triple-negative breast cancer
por: Rashid, Narmeen S., et al.
Publicado: (2021) -
Stratification of Tamoxifen Synergistic Combinations for the Treatment of ER+ Breast Cancer
por: Zboril, Emily K., et al.
Publicado: (2023) -
Efficacy of Providing the PI3K p110α Inhibitor BYL719 (Alpelisib) to Middle-Aged Mice in Their Diet
por: Hedges, Christopher P., et al.
Publicado: (2021) -
PI3k inhibitors (BKM120 and BYL719) as radiosensitizers for head and neck squamous cell carcinoma during radiotherapy
por: Chuang, Fu-Cheng, et al.
Publicado: (2021)